Initial data from the first five patients indicate positive trends for all primary and secondary safety and efficacy endpoints in AzurRx’s Phase 2 Clinical Study for MS1819-SD, in combination with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback